ADXS vs. HOTH, XBIO, SONN, FWBI, VCNX, KTRA, KZIA, PXMD, AIMD, and SHPH
Should you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Hoth Therapeutics (HOTH), Xenetic Biosciences (XBIO), Sonnet BioTherapeutics (SONN), First Wave BioPharma (FWBI), Vaccinex (VCNX), Kintara Therapeutics (KTRA), Kazia Therapeutics (KZIA), PaxMedica (PXMD), Ainos (AIMD), and Shuttle Pharmaceuticals (SHPH). These companies are all part of the "pharmaceutical preparations" industry.
Ayala Pharmaceuticals (NASDAQ:ADXS) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.
7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 3.3% of Hoth Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Hoth Therapeutics had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Hoth Therapeutics and 0 mentions for Ayala Pharmaceuticals. Hoth Therapeutics' average media sentiment score of 1.00 beat Ayala Pharmaceuticals' score of 0.00 indicating that Hoth Therapeutics is being referred to more favorably in the news media.
Ayala Pharmaceuticals has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Hoth Therapeutics has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.
Hoth Therapeutics received 65 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 63.11% of users gave Hoth Therapeutics an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote.
Hoth Therapeutics has lower revenue, but higher earnings than Ayala Pharmaceuticals. Hoth Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Hoth Therapeutics has a consensus target price of $4.00, indicating a potential upside of 229.22%. Given Hoth Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Hoth Therapeutics is more favorable than Ayala Pharmaceuticals.
Hoth Therapeutics' return on equity of -76.28% beat Ayala Pharmaceuticals' return on equity.
Summary
Hoth Therapeutics beats Ayala Pharmaceuticals on 12 of the 16 factors compared between the two stocks.
Get Ayala Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ayala Pharmaceuticals Competitors List
Related Companies and Tools
